london-journal-of-medical-and-health-research London Journal of Medical and Health Research 2515-5784 2515-5792 JournalsPress 88564 Multimodality Treatment in Case of Peritoneal Mesothelioma – A Case Report and Review of Literature Peritoneal Mesothelioma: Neoadjuvant+CRS+HIPEC 29 12 2022 22 13 15 18

Peritoneal mesothelioma (PeM) represents around one fifth to one third of all mesothelioma. The incidence of PeM is approximately one per 1,000,000. Giving the fact of non-specificity of the symptoms, the diagnoses is usually delay. Multimodality treatment with adjuvant chemotherapy and cytoreductive surgery (CRS) and hyper thermic intraperitoneal chemotherapy (HIPEC) improve the long term survival. Herein, this is a presentation of patient diagnosed with peritoneal mesothelioma with a review of literature.

 Full Text

Peritoneal mesothelioma (PeM) represents around one fifth to one third of all mesothelioma. The incidence of PeM is approximately one per 1,000,000. Giving the fact of non-specificity of the symptoms, the diagnoses is usually delay. Multimodality treatment with adjuvant chemotherapy and cytoreductive surgery (CRS) and hyper thermic intraperitoneal chemotherapy (HIPEC) improve the long term survival. Herein, this is a presentation of patient diagnosed with peritoneal mesothelioma with a review of literature.